Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa
Key facts
- Who runs it
- GlaxoSmithKline
- Where
- Burkina Faso, Ghana, Kenya, Malawi, Senegal, and Tanzania10 sites in 6 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 54,115 people enrolled
- Started
- 22 Oct 2014
- Ended
- 6 Jul 2024
- Type of study
- Interventional, 10 groups
- Treatments tested
- Assessment of body temperature
- Blood sampling
- Record updated
- 24 July 2025
Who can take part
- Age
- 6 months to 9 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Participants whose parent(s)/Legally Acceptable Representative(s) [LAR(s)], in the opinion of the investigator, could and would comply with the requirements of the protocol
- A male or female aged 6 months to under 10 years at the time of the survey
- Signed informed consent or thumb-printed and witnessed informed consent was obtained from the parent(s)/LAR(s) of the child
Who cannot take part
- Had current active participation in any trial involving administration of an investigational malaria vaccine or malaria drug
- Child was in care
This trial has no sites in United States.
It has sites in 6 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This epidemiology study was conducted in parallel with the EPI-MAL-002 (NCT02374450) and EPI-MAL-003 (NCT03855995) studies, enrolling participants from the same health and demographic surveillance system (HDSS) (or equivalent system) populations. The co-primary objectives were to produce longitudinal estimates of parasite prevalence in humans and to record the usage of malaria control measures in areas where the EPI-MAL-002 and EPI-MAL-003 studies were conducted.
The 10 groups in the trial
- Survey 1 GroupOther group
Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 1.
Treatment: Assessment of body temperature and Blood sampling
- Survey 2 GroupOther group
Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 2.
Treatment: Assessment of body temperature and Blood sampling
- Survey 3 GroupOther group
Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 3.
Treatment: Assessment of body temperature and Blood sampling
- Survey 4 GroupOther group
Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 4.
Treatment: Assessment of body temperature and Blood sampling
- Survey 5 GroupOther group
Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 5.
Treatment: Assessment of body temperature and Blood sampling
- Survey 6 GroupOther group
Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 6.
Treatment: Assessment of body temperature and Blood sampling
- Survey 7 GroupOther group
Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 7.
Treatment: Assessment of body temperature and Blood sampling
- Survey 8 GroupOther group
Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 8.
Treatment: Assessment of body temperature and Blood sampling
- Survey 9 GroupOther group
Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 9.
Treatment: Assessment of body temperature and Blood sampling
- Survey 10 GroupOther group
Participants aged 6 months to \<10 years, enrolled in the current EPI-MAL-005 study from sites that participated in EPI-MAL-002/-003, during study Year 10.
Treatment: Assessment of body temperature and Blood sampling
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- An Epidemiology Study to Assess Plasmodium Falciparum Parasite Prevalence and Malaria Control Measures in Catchment Areas of Two Interventional Studies Pre- and Post RTS,S/AS01E Introduction (EPI MAL-002 and EPI-MAL-003) to Assess, in Field Conditions, Vaccine Benefit: Risk in Children in Sub Saharan Africa
- Record updated
- 24 July 2025